PHARMASEAL has announced a second major release of its Engility CTMS platform. The platform includes enhanced capabilities to its enterprise CTMS, including site monitoring, issue management and global access management, simplifying control and operation of clinical trials.
With a focus on configurability and collaboration, the Engility CTMS monitoring module has been designed to address many of the pain points with traditional monitoring solutions, to enable effective oversight of clinical trials. It provides a workspace to manage all monitoring visits (onsite/remote/telephone) via a simple, intuitive interface to support working in the system.
The globalization of clinical trials poses additional challenges and coordination is required of sponsors to ensure timely communication of new findings among all stakeholders in all regions. The issue management and globalized access management functionality of the platform enables users to manage all issues at study, country, site and subject level. Protocol deviations and other study issues can be handled in a central, collaborative, easy to use interface with full visibility of actions being taken.
“Engility CTMS is a SaaS cloud platform built with agility at its core and engineered to evolve. The platform is designed to rapidly deliver new product updates within a managed validation framework facilitating accelerated innovation,” Daljit Cheema, CEO and Founder of PHARMASEAL said. “PHARMASEALS’ collective passion for continuous innovation leads to enhanced capabilities, such as the monitoring module, so that biopharmaceutical sponsors and medical device companies of all sizes can proactively and collaboratively adopt an innovative approach to help provide objectivity and accuracy to the clinical monitoring process.”